ANTI-FACTOR B ANTIBODY, PHARMACEUTICAL COMPOSITION THAT CAN BE USED FOR THE TREATMENT OF DISEASES OF THE COMPLEMENT SYSTEM, AND USES THEREOF

摘要

The invention relates to an anti-factor B antibody that blocks the generation of the alternative complement pathway C3 convertase that can be used to prevent or modulate the activation or amplification of the activation of the complement system. A specific form of this antibody is the monoclonal antibody anti-factor B produced by the hybridoma FB-28.4.2 deposited at the ECACC on 13 November 2012 under reference number 12111301. In addition, the invention relates to a pharmaceutical composition that can be used for the treatment of diseases associated with the complement system, such as, for example, atypical hemolytic uremic syndrome (aHUS) or paroxysmal nocturnal hemoglobinuria (PNH). The invention further relates to a biotechnological complex that can be used to perform tests in order to identify and design medicaments or pharmaceutical compositions that inhibit the complement system.